S'abonner

The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity–United States, 2000 to 2006 - 20/10/11

Doi : 10.1016/j.jaad.2011.04.036 
Donatus U. Ekwueme, MS, PhD a, , Gery P. Guy, MPH, PhD a, Chunyu Li, MD, PhD a, Sun Hee Rim, MPH a, Pratibha Parelkar, MPH b, Suephy C. Chen, MS, MD c, d
a Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 
b Department of Health Promotion and Behavioral Sciences, University of Texas, Houston, Texas 
c Department of Dermatology, Emory University, Atlanta, Georgia 
d Division of Dermatology, Atlanta Department of Veterans Affairs Medical Center, Atlanta, Georgia 

Reprint requests: Donatus U. Ekwueme, PhD, MS, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, MS K-55, Atlanta, GA 30341.

Abstract

Background

Cutaneous melanoma is the most deadly form of skin cancer with more than 8000 deaths per year in the United States. The health burden and economic costs associated with melanoma mortality by race/ethnicity have not been appropriately addressed.

Objective

We sought to quantify the health burden and economic costs associated with melanoma mortality among racial/ethnic groups in the United States.

Methods

We used 2000 to 2006 national mortality data and US life tables to estimate the number of deaths, and years of potential life lost (YPLL). Further, we estimated the economic costs of melanoma mortality in terms of productivity losses. All the estimates were stratified by race/ethnicity and sex.

Results

From 2000 to 2006, we estimated an increase of 13,349 (8.7%) YPLL because of melanoma mortality compared with a 2.8% increase among all malignant cancers across all race/ethnicity. On average, an individual in the United States loses 20.4 years of potential life during their lifetime as a result of melanoma mortality compared with 16.6 years for all malignant cancers. The estimated annual productivity loss attributed to melanoma mortality was $3.5 billion. Our estimates suggest that an individual who died from melanoma in 2000 through 2006 would lose an average of $413,370 in forgone lifetime earnings. YPLL rates and total productivity losses are much higher among non-Hispanic whites as compared with non-Hispanic blacks and Hispanics.

Limitations

The estimated economic costs did not include treatment, morbidity, and intangible costs.

Conclusions

We estimated substantial YPLL and productivity losses as a result of melanoma mortality during an individual’s lifetime. By examining the burden by race/ethnicity, this study provides useful information to assist policy-makers in making informed resource allocation decisions regarding cutaneous melanoma mortality.

Le texte complet de cet article est disponible en PDF.

Key words : cancer, economic cost, melanoma, mortality, productivity loss, race/ethnicity, years of potential life lost

Abbreviations used : HCA, PVFLE, SEER, YPLL


Plan


 Publication of this supplement to the JAAD was supported by the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC).
 Conflicts of interest: None declared.
 The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions, recommendations, or official position of the journal editors or the Centers for Disease Control and Prevention.
 Please see Appendix 1 for a glossary of technical terms used in this article.


© 2011  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 65 - N° 5S1

P. S133.e1-S133.e12 - novembre 2011 Retour au numéro
Article précédent Article précédent
  • Melanoma reporting to central cancer registries by US dermatologists: An analysis of the persistent knowledge and practice gap
  • Todd V. Cartee, Seema P. Kini, Suephy C. Chen
| Article suivant Article suivant
  • CME examination

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.